P/E ratio for WuXi Biologics (WXXWY)
P/E ratio at the end of 2023: 32.1
According to WuXi Biologics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 36.2912. At the end of 2023 the company had a P/E ratio of 32.1.
P/E ratio history for WuXi Biologics from 2017 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2023 | 32.1 | -34.5% |
| 2022 | 49.0 | -46.11% |
| 2021 | 91.0 | -52.92% |
| 2020 | 193 | 76.09% |
| 2019 | 110 | 30.87% |
| 2018 | 83.9 | -45% |
| 2017 | 152 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.